These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1173501)

  • 1. Relation between thyroid function and serum levels of long-acting thyroid stimulator.
    Davis JC; Hipkin LJ; Summers VK; Gimlette TM
    Acta Endocrinol (Copenh); 1975 Jul; 79(3):451-8. PubMed ID: 1173501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between long-acting thyroid stimulator protector level and thyroid 131-I uptake in thyrotoxicosis.
    Adams DD; Kennedy TH; Stewart RD
    Br Med J; 1974 Apr; 2(5912):199-201. PubMed ID: 4406686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pituitary-thyroid function in thyrotoxic patients in relation to long-acting thyroid stimulator (LATS) levels.
    Fukuchi M; Matsuoka T; Inoue T; Miyai K; Kumahara Y
    Acta Endocrinol (Copenh); 1970 Dec; 65(4):577-82. PubMed ID: 5536685
    [No Abstract]   [Full Text] [Related]  

  • 4. The pathogenesis of thyrotoxicosis the discovery of LATS.
    Adams DD
    N Z Med J; 1975 Jan; 81(531):15-7. PubMed ID: 1055308
    [No Abstract]   [Full Text] [Related]  

  • 5. Dissociation of serum LATS activity and hyperfunction and autonomy of the thyroid gland in Graves' disease.
    Hennemann G; Dolman A; Docter R; De Reus A; Van Zijl J
    J Clin Endocrinol Metab; 1975 Jun; 40(6):935-41. PubMed ID: 1173367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient thyrotoxicosis in an infant delivered to a long-acting thyroid stimulator (LATS)- and LATS protector-negative, thyroid-stimulating antibody-positive woman with Hashimoto's thyroiditis.
    Hoffman WH; Sahasrananan P; Ferandos SS; Burek CL; Rose NR
    J Clin Endocrinol Metab; 1982 Feb; 54(2):354-6. PubMed ID: 6119322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A STANDARD FOR THE LONG-ACTING THYROID STIMULATOR (LATS) IN THE SERUM OF PATIENTS WITH THYROTOXICOSIS.
    DORRINGTON KJ; MUNRO DS
    J Endocrinol; 1964 Nov; 31():21-8. PubMed ID: 14231127
    [No Abstract]   [Full Text] [Related]  

  • 8. Dissociation of serum LATS content and thyroid suppressibility during treatment of hyperthyroidism.
    Chopra IJ; Solomon DH; Johnson DE; Chopra U; Fischer DA
    J Clin Endocrinol Metab; 1970 Apr; 30(4):524-8. PubMed ID: 5435290
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of long-acting thyroid stimulator (LATS) and LATS protector on human thyroid adenyl cyclase activity.
    Kendall-Taylor P
    Br Med J; 1973 Jul; 3(5871):72-5. PubMed ID: 4740444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placental transmission of thyroid-stimulating immunoglobulins.
    Dirmikis SM; Munro DS
    Br Med J; 1975 Jun; 2(5972):665-6. PubMed ID: 1173561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of serum long-acting thyroid stimulator (LATS) in relation to exophthalmos after therapy for thyrotoxicosis.
    Hetzel BS; Mason EK; Wang HK
    Australas Ann Med; 1968 Nov; 17(4):307-11. PubMed ID: 4178378
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.
    Hardisty CA; Hanford L; Humphries H; Munro DS
    Clin Endocrinol (Oxf); 1981 Jun; 14(6):631-9. PubMed ID: 6895353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The long-acting thyroid stimulator (LATS) in untreated and I-131 treated hyperthyreoses, following total thyroidectomy, as well as its relation to thyroid antibodies].
    Ziemke A; Weisbecker L; Uthgenannt H; Schemmel K; Müller W; Heesen H; Eickenbusch W
    Klin Wochenschr; 1968 Oct; 46(19):1025-7. PubMed ID: 5727481
    [No Abstract]   [Full Text] [Related]  

  • 14. Positive correlation of the long-acting thyroid stimulator (LATS) with the percentage of endogenously labelled 131 I triiodothyronine in the plasma of hyperthyroid patients.
    Emrich D; Albani M; zur Mühlen A von
    Acta Endocrinol (Copenh); 1971 Nov; 68(3):445-50. PubMed ID: 4107957
    [No Abstract]   [Full Text] [Related]  

  • 15. Occurrence in thyrotoxicosis of a gamma globulin which protects LATS from neutralization by an extract of thyroid gland.
    Adams DD; Kennedy TH
    J Clin Endocrinol Metab; 1967 Feb; 27(2):173-7. PubMed ID: 4163610
    [No Abstract]   [Full Text] [Related]  

  • 16. The interaction between LATS and thyroid tissue in vitro.
    Smith BR; Munro DS
    Clin Sci; 1969 Oct; 37(2):566. PubMed ID: 5359011
    [No Abstract]   [Full Text] [Related]  

  • 17. The long-acting thyroid stimulator and the result of I 131 treatment for thyrotoxicosis.
    Martin FI; Larkins RG; Alford FP; Andrews JT; Greenberg PB; Melick RA; Penington JS
    Aust N Z J Med; 1972 May; 2(2):168-72. PubMed ID: 4116447
    [No Abstract]   [Full Text] [Related]  

  • 18. LATS protector, the human thyroid stimulator.
    Adams DD
    N Z Med J; 1975 Jan; 81(531):22-3. PubMed ID: 1055310
    [No Abstract]   [Full Text] [Related]  

  • 19. [TSH and the "long-acting thyroid stimulator" (LATS) in patients with compensated hyperthyroidism].
    zur Mühlen A von ; Hesch RD; von Lilienfeld H; Emrich D
    Acta Endocrinol Suppl (Copenh); 1971; 152():86. PubMed ID: 5313711
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence that both long-acting thyroid stimulator and long-acting thyroid stimulator-protector stimulate the human thyroid gland.
    Holmes SD; Dirmikis SM; Martin TJ; Munro DS
    J Endocrinol; 1979 Feb; 80(2):215-21. PubMed ID: 220366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.